CAC
IMCR icon

Cowen and Company’s Immunocore IMCR Stock Holding History

Cowen and Company’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-121,092
Closed -$7.87M – 668
2024
Q1 		$7.87M Sell
121,092
-415,395
-77% -$28.5M 0.3% 32
2023
Q4 		$36.7M Buy
536,487
+76,451
+17% +$3.97M 2.4% 8
2023
Q3 		$23.9M Hold
460,036
– – 1.67% 13
2023
Q2 		$27.6M Buy
460,036
+54,862
+14% +$3.13M 2.29% 11
2023
Q1 		$20M Hold
405,174
– – 2.35% 10
2022
Q4 		$23.1M Sell
405,174
-606,496
-60% -$34.1M 2.42% 13
2022
Q3 		$47.5M Buy
+1,011,670
New +$48.2M 4.54% 4

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Cowen and Company's IMCR Position: Q2 2024 in Review

Cowen and Company sold out of Immunocore (IMCR) in Q2 2024, closing a stake of 121,092 shares — an estimated $7.87M sold.

Cowen and Company first reported a position in IMCR in Q3 2022 and held it in 7 quarters. The position peaked at $47.5M in Q3 2022. 138 funds tracked by Wall St. Rank hold IMCR as of Q2 2024.

  • Cowen and Company reported no remaining Immunocore position as of Q2 2024 after selling out during the quarter.
  • Cowen and Company sold 121,092 Immunocore shares in Q2 2024, an estimated $7.87M.
  • Cowen and Company first reported a position in Immunocore in Q3 2022 and held it in 7 quarters.
  • Cowen and Company's Immunocore position peaked at $47.5M in Q3 2022.
  • 138 funds tracked by Wall St. Rank held Immunocore as of Q2 2024.

Based on Cowen and Company's 13F filing for Q2 2024, filed 7 Aug 2024.